GeneDx Holdings Corp.

NASDAQ:WGS

Medical - Healthcare Information Services

Healthcare
$51.96 +2.69%

+$1.52 today

Market cap
$1.56B
Beta
1.97
P/E (TTM)
-21.8
EPS (TTM)
-$2.65
52W Low $32.21High $170.87

Volume 1.71M

Average 1.28M

WGS Acquisitions (Net)

Cash paid for acquiring businesses, net of cash acquired.

GeneDx Holdings Corp.NASDAQ: WGS

Acquisitions (Net) · Q2 FY2026 · quarter ended Jun 2026

Acquisitions (net) outflow grows to $0

Q2 FY2026 acquisitions (net) was $0, compared with $0 a year earlier. Trailing-twelve-month acquisitions (net) was -$32.86M. Over 3 fiscal years it compounded at -36.3% a year.

Context

  • Acquisitions (net) amounted to 7.7% of revenue in FY2025, up 7.7 pp from a year earlier.
  • Acquisitions (net) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly acquisitions (net) holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$8.21M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
-$32.86M— YoY
LTMJun 2026
-$32.86M— YoY
Acquisitions (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR-36.3%——
5-year CAGR——
10-year CAGR——

Acquisitions (Net) history

USD · from the cash flow

Latest · FY2025
(32.86M) USD
Year-over-year change
—

Acquisitions (Net) vs competitors

How WGS compares with its peers on the latest reported figures

  • WGS's LTM Jun 2026 acquisitions (net) of $32.86M is the 2nd largest of the 9 companies compared; the peer median is $0.
  • Acquisitions (net) amounts to 7.2% of revenue for WGS, versus a peer median of 0.0%.
WGS Competitors Peer median
Acquisitions (Net) for WGS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FLGTFulgent Genetics, Inc.LTM Mar 2026$51.79M ——16.2%
WGSGeneDx Holdings Corp.LTM Jun 2026$32.86M —-36.3%7.2%
CSTLCastle Biosciences, Inc.LTM Mar 2026$18.7M —-11.4%5.5%
NEONeoGenomics, Inc.LTM Jun 2026$463K -92.3%—0.1%
PSNLPersonalis, Inc.LTM Mar 2026$120K ——0.2%
BLLNBillionToOne, Inc.LTM Jun 2026$0 ——0.0%
MYGNMyriad Genetics, Inc.LTM Mar 2026$0 ——0.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$0 ——0.0%
MDXHMDxHealth S.A.FY2025$0 ——0.0%
Peer median (excluding WGS) $0-92.3%-11.4%0.0%

Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(245.39M)(548.98M)(175.77M)(52.29M)(21.02M)
Depreciation & Amortization21.81M59.31M33.73M21.95M25.22M
Deferred Income Tax0(49.12M)(926K)(343K)0
Stock-Based Compensation219.42M41.98M(326K)9.14M32.16M
Change in Working Capital8.08M36.13M(38.24M)(24.75M)(15.6M)
Accounts Receivables5.54M5.53M10.26M(5.42M)(36.23M)
Inventory(10.62M)4.6M975K(2.59M)(3.44M)
Accounts Payables034.46M(46.95M)(20.46M)12.1M
Other Working Capital13.17M(8.46M)(2.53M)3.72M11.97M
Other Non-Cash Items(194.35M)141.53M1.38M17.79M12.51M
Operating Cash Flow(190.43M)(319.16M)(180.15M)(28.5M)33.28M
Capital Expenditures(20.79M)(14.32M)(5.71M)(5.49M)(19.02M)
Acquisitions (Net)0(127M)(8.11M)0(32.86M)
Purchases of Investments00(47.67M)(66.3M)(55.68M)
Sales of Investments0017.77M41.66M46.03M
Other Investing Activities(11.39M)0000
Investing Cash Flow(20.79M)(141.33M)(43.73M)(30.13M)(61.52M)
Debt Repayment(13.47M)(3.29M)42.95M(3.23M)(3.66M)
Common Stock Issued442.68M197.66M143M46.5M51.69M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities64.51M2.95M285K891K0
Financing Cash Flow493.73M197.32M186.24M44.16M48.03M
Effect of Forex Changes00(87K)00
Net Change in Cash282.51M(263.17M)(37.72M)(14.47M)19.79M
Free Cash Flow(211.22M)(333.48M)(185.86M)(33.99M)14.26M

GeneDx Holdings Corp.

NASDAQ:WGS

Intrinsic Alpha fair value

Locked

Current Price

$51.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.